Alcoholic Liver Disease Clinical Trial
Official title:
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
Verified date | January 2018 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a research study of a text-messaging intervention to reduce alcohol relapse risk in pre-transplant liver transplantation patients. This study is an 8-week, randomized controlled pilot trial to investigate the feasibility and acceptability of a text-messaging intervention for alcohol relapse prevention and stress reduction in 20 liver transplant patients with alcohol-related liver disease. The goals of the study are (1) to develop a mobile, SMS-based stress reduction and alcohol use intervention for pre- liver transplant patients with alcohol-related liver disease (ALD) and (2) to evaluate the feasibility and acceptability of the mobile intervention and its effect on rates of alcohol consumption compared to a Standard Care condition in a liver transplantation center.
Status | Completed |
Enrollment | 15 |
Est. completion date | May 6, 2014 |
Est. primary completion date | March 25, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - at least 18 years of age; - diagnosis of alcohol-related liver disease; - currently in evaluation for UNOS listing as a liver transplant candidate; - last reported use of any alcohol within the past 1 year; - willingness to receive and respond to multiple text messages per day. Exclusion Criteria: - unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, or dementia. |
Country | Name | City | State |
---|---|---|---|
United States | Yale Transplantation Center/Yale-New Haven Hospital | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Free C, Knight R, Robertson S, Whittaker R, Edwards P, Zhou W, Rodgers A, Cairns J, Kenward MG, Roberts I. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet. 2011 Jul 2;378(9785):49-55. doi: 10.1016/S0140-6736(11)60701-0. — View Citation
Heron KE, Smyth JM. Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol. 2010 Feb;15(Pt 1):1-39. doi: 10.1348/135910709X466063. Epub 2009 Jul 28. Review. — View Citation
Pfitzmann R, Schwenzer J, Rayes N, Seehofer D, Neuhaus R, Nüssler NC. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007 Feb;13(2):197-205. — View Citation
Webb MS, Hendricks PS, Brandon TH. Expectancy priming of smoking cessation messages enhances the placebo effect of tailored interventions. Health Psychol. 2007 Sep;26(5):598-609. — View Citation
Weitzel JA, Bernhardt JM, Usdan S, Mays D, Glanz K. Using wireless handheld computers and tailored text messaging to reduce negative consequences of drinking alcohol. J Stud Alcohol Drugs. 2007 Jul;68(4):534-7. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intervention Feasibility Evaluation | Patterns of text message usage | 8 weeks | |
Primary | Alcohol Abstinence Rates | Biologically confirmed (EtG) rates of abstinence from alcohol | 8 Weeks | |
Secondary | Subjective Alcohol Abstinence Rates | Self-reports of any days drinking during treatment and self-reports of alcohol craving | 8 Weeks | |
Secondary | Stress Ratings | Perceived Stress Scale (PSS). Self-report 4 item scale with each item on a 0-4 scale (maximum score = 16). Higher scores indicate higher levels of stress. | 8 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00708617 -
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
|
N/A | |
Completed |
NCT00990639 -
Effect of Candesartan in Alcoholic Liver Fibrosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04106518 -
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
|
||
Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Completed |
NCT01501162 -
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
|
Phase 4 | |
Recruiting |
NCT05895890 -
French National MICMAF Cohort
|
||
Completed |
NCT04557774 -
Cognitive Function of Alcoholic Compensated Liver Cirrhosis
|
||
Recruiting |
NCT03267069 -
Evaluating Alcohol Use in Alcoholic Liver Disease
|
||
Recruiting |
NCT03295812 -
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
|
N/A | |
Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
Not yet recruiting |
NCT03503708 -
Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
|
N/A | |
Completed |
NCT02796469 -
Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT02140294 -
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT03209791 -
Ethanol Induces Skeletal Muscle Autophagy
|
||
Recruiting |
NCT04736966 -
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
|
Phase 1 | |
Recruiting |
NCT04400604 -
Study of Alcohol-related Liver Disease in Europe
|
||
Completed |
NCT01711125 -
Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT03863730 -
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota
|
N/A | |
Not yet recruiting |
NCT06307964 -
Intra-Hepatic Microbiota in Alcoholic Hepatitis
|